newsfilter
← Latest News
GlobeNewswire·

Applied Therapeutics Reports Third Quarter 2024 Financial Results

- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for